Immune tolerance therapy in patients with acquired hemophilia.
Acquired hemophilia is a rare disorder with an estimated annual incidence of 0.2-1 cases per million individuals. The etiology of the disorder remains obscure, although approximately half of all cases are associated with other underlying conditions. In acquired hemophilia, the severe hemorrhagic diathesis is caused by the development of autoantibodies directed against a clotting factor, most commonly factor VIII. These autoantibodies inhibit normal coagulation and lead to bleeding complications, which can be life-threatening in a high percentage of cases. Prompt diagnosis and appropriate management of the disorder enable effective control; the short- and long-term aims of therapy are to terminate the acute bleed and eliminate or reduce the inhibitor, respectively. Immune tolerance therapy has been shown to successfully eradicate or suppress inhibitors in patients with congenital hemophilia A and may be applicable to patients with acquired hemophilia. Here we present preliminary data on the use of immune tolerance therapy in patients with acquired hemophilia and discuss possible treatment strategies.
von Depka
Mario
M
Department of Hematology, Haemostasis and Oncology, Hannover Medical School, Germany. depka.mario@mh-hannover.de
D001323:Autoantibodies / Q000276:immunology*; D001777:Blood Coagulation / Q000276:immunology; D019774:Blood Coagulation Factor Inhibitors / Q000276:immunology; D005169:Factor VIII / Q000276:immunology* / Q000627:therapeutic use*; D006467:Hemophilia A / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance
D001323:Autoantibodies; D019774:Blood Coagulation Factor Inhibitors; D005169:Factor VIII